A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Inclusion Criteria: * Men and women Aged ≥18 years * Hospitalized subjects who have confirmed COVID-19 infection and have evidence of pneumonia: * Subjects who are eligible for diagnosis/evaluation to chest X-ray or chest CT * Women of childbearing potential (including women in post menopause for less than 2 years) must use a medically acceptable forms of birth control and agree to continue its use during the study * Subjects (or legally authorized representative) should be able to understand and agree to comply with the clinical trial and to provide a written consent document prior to initiation of any study procedure Exclusion Criteria: * Subjects who have a record of HIV or AIDS * Subject has a serious chronic disease * Active bleeding or ongoing clinical condition deemed at high risk of bleeding contraindicating anticoagulant treatment * Pregnant or lactating females * Subjects with liver cirrhosis whose Child-Pugh score is B or C * Subjects who have liver disease abnormalities with ALT or AST \> 5 times ULN * Estimated glomerular filtration rate (eGFR) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration) * QTcB or QTcF \>500ms * Subjects who have clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) in medical history * Subjects with rapidly deteriorating clinical condition or low likelihood to complete the study according to the investigator's opinion * Subjects who are not appropriate for the study, as the investigator's opinion * Subjects who have hypersensitivity to the investigational drug * Subjects participated in any other clinical trial (including drugs for the treatment of COVID-19) 3 months prior to screening